Rather than addressing surface level concerns, these ingredients help your skin behave more like younger, healthier skin.
Orforglipron is the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot ...
In collaboration with researchers in South Korea, a team from The Hospital for Sick Children (SickKids) has discovered a ...
According to David A. Ricks, chair and CEO of Eli Lilly, current utilization of GLP-1s remains low relative to the population that could benefit, citing “fewer than 1 in 10 people who could benefit ...
Detailed results from the phase 3 TEMPO trials show tavapadon offers a mechanistically distinct approach for managing motor ...
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population; Phase 1b data demonstrate ...
Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of use, including simplified dosing ...
Morning Overview on MSN
Scientists use bacteria to turn PET plastic waste into a Parkinson’s drug
Researchers at the University of Edinburgh have engineered Escherichia coli bacteria to convert a chemical building block of ...
Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing ...
If you've been following the weight-loss medication revolution, you've likely heard about Wegovy injections. But now there's ...
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2025, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results